Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease

• Main Authors: Shin-Ichi Ueno, Shinji Saiki, Motoki Fujimaki, Haruka Takeshige-Amano, Taku Hatano, Genko Oyama, Kei-Ichi Ishikawa, Akihiro Yamaguchi, Shuko Nojiri, Wado Akamatsu, Nobutaka Hattori
• Format: Article
• Language: English
• Published: MDPI AG 2018-12-01
• Series: Cells
• Subjects: Parkinson’s disease; fatty acid β-oxidation; long-chain acylcarnitine
• Online Access: http://www.mdpi.com/2073-4409/8/1/14

Although many experimental studies have shown the favorable effects of zonisamide on mitochondria using models of Parkinson’s disease (PD), the influence of zonisamide on metabolism in PD patients remains unclear. To assess metabolic status under zonisamide treatment in PD, we performed a pilot study using a comprehensive metabolome analysis. Plasma samples were collected for at least one year from 30 patients with PD: 10 without zonisamide medication and 20 with zonisamide medication. We performed comprehensive metabolome analyses of plasma with capillary electrophoresis time-of-flight mass spectrometry and liquid chromatography time-of-flight mass spectrometry. We also measured disease severity using Hoehn and Yahr (H&Y) staging and the Unified Parkinson’s Disease Rating Scale (UPDRS) motor section, and analyzed blood chemistry. In PD with zonisamide treatment, 15 long-chain acylcarnitines (LCACs) tended to be increased, of which four (AC(12:0), AC(12:1)-1, AC(16:1), and AC(16:2)) showed statistical significance. Of these, two LCACs (AC(16:1) and AC(16:2)) were also identified by partial least squares analysis. There was no association of any LCAC with age, disease severity, levodopa daily dose, or levodopa equivalent dose. Because an upregulation of LCACs implies improvement of mitochondrial β-oxidation, zonisamide might be beneficial for mitochondrial β-oxidation, which is suppressed in PD.